Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older
Prior exposure to 4-6 cycles of Pem/Carbo/Pembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.
PS 0-1
You may not be if
Presence of a driver mutation that is susceptible to targeted therapy
Other active invasive malignancy requiring ongoing therapy
Grade 2 or higher sensory neuropathy
Evidence of untreated brain metastases
History of bleeding diatheses or recent, antecedent hemoptysis (\> 1/2 teaspoon in prior 2 months)
